PPH Legal Blog

Bayer Schering Pharma has reported positive findings during the first round of clinical trials for its oral pulmonary hypertension treatment, Riociguat. The development of this drug is the first in its class of vasodilating agents.

The trials, being successful so far, will now move onto a Phase III study in late 2008 to determine the full effect of the drug. The Phase II trial showed that the treatment was well tolerated by patients and remained a safe treatment option with no serious side effects.

Head of Bayer’s Global Development team, Kernal Malik, M.D., said, “Riociguat has the potential to overcome limitations of current standards of care in pulmonary hypertension.”

If the Phase III trial is as positive as predicted, this could open the door for many patients who have not had a viable treatment option for their condition. Bayer remains dedicated to treating cardiovascular diseases, as it as done for many years.

If you are suffering from primary pulmonary hypertension because of a diet pill that you took, speak with a PPH lawyer immediately. Contact the PPH lawyers of Williams Kherkher today by calling 866-950-9000.